APGE · Apogee Therapeutics, Inc.
$134.71
+0.14 (+0.10%)
At close · Aug 19
Going-concern doubt
— cleared Aug 10, 2026
The latest filing states the doubt was alleviated.
“The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the accompanying consolidated financial statements are issued. ... Based on the Company's current operating plan, it estimates that its existing cash and cash equivalents of $105.6 million, marketable securities of $866.4 million and long-term marketable securities of $321.9 million as of June 30, 2026, will be sufficient to enable the Company to fund its operating expenses and capital requirements through at least the next 12 months from the issuance of these consolidated financial statements.”View the 10-Q filed Aug 10, 2026
Market Cap
$10.19B
Shares
75.69M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2024-08 | — | $300,000,000 | $157,800,000 as of 2026-03-31 | — | 10-Q , filed 2026-05-11 |
Key facts
CIK
1974640
CUSIP
03770N101
13F (30d)
278 filings
276 filers
Visit website
Investor relations